Clinical Education InitiativeMenu
Home > Courses > Advances in the Treatment of HCV & HCV/HIV Coinfection

Advances in the Treatment of HCV & HCV/HIV Coinfection

Advances in the Treatment of HCV & HCV/HIV Coinfection
Sorry, this learning module is not available for mobile devices.
Original Presentation: 12/8/2015
Web Posting: 4/4/2016
CE Expiration: 12/07/2018
  • Dost Sarpel, MD
    Viral Hepatology Fellow, Division of Liver Diseases
    Icahn School of Medicine, Mount Sinai
Learning Objectives
At the completion of this educational session, participants will:
  1. Appreciate the history of chronic HCV disease and treatment with and without HIV coinfection.
  2. Understand the use of directly acting agents (DAAs) for HCV.
  3. Be aware of the importance of resistance to DAAs.
Presenter Bio
Dost Sarpel, MD
Dost Sarpel is currently a Viral Hepatology fellow under the mentorship of Dr. Douglas Dieterich at Icahn School of Medicine at Mount Sinai. He completed medical school at University at Buffalo School of Medicine and Biomedical Sciences, followed by a residency in Internal Medicine at The George Washington University Hospital. He then completed his Infectious Disease fellowship at The George Washington University Hospital in 2012. For the past three years he worked at a private practice Infectious Disease group in the East Bay outside of San Francisco, making partner physician in 2014. Dr. Sarpel then made the decision to pursue additional training because of his strong interest in viral hepatitis and the new direct acting antiviral (DAA) therapies. Currently his viral hepatology fellowship research projects involve hepatitis C patients who have failed DAA therapy, improving hepatocellularcarcinoma screening in chronic hepatitis B and C infected patients, and true cause of death in hepatitis C infected patients.
Continuing Education Credit

This CME activity was approved for AMA PRA Category 1 Credit™ on December 8, 2015 and will terminate December 7, 2018.

The target audience is all physicians, NPs and PAs involved or interested in HIV education.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (MSSNY) and the Physicians’ Research Network (PRN). MSSNY is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Society of the State of New York designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with extent of their participation in the activity.

Disclosure Statement

Policies and standards of MSSNY require that speakers and planners for CME activities disclose any relevant financial relationships they may have with commercial interests whose products, devices or services may be discussed in the content of a CME activity.

  • Dr. James Braun (Planner/Course Director) had no relevant financial relationships to disclose.
  • Dr. Sarpel (Presenter) had no relevant financial relationships to disclose. Dr. Sarpel submitted his slides in advance for adequate peer review, and will support his presentation and clinical recommendations with the best available evidence from the medical literature.

 Financial Support

This meeting of the Physicians’ Research Network (PRN) and enduring material were funded in part by educational grants from: Bristol-Myers Squibb, Gilead Sciences, Janssen Pharmaceuticals, Merck & Co, and ViiV Healthcare.


  • This online video and post-activity evaluation are one hour in length.  After you complete the video portion of this educational activity
  • there will be a post-activity evaluation and quiz. 
  • You must achieve at least 70% correct to receive your CME certificate. 
  • If successful, you will be provided instructions to print your CME certificate at the completion of this activity.
PRN Learning Modules